9-(6-Phenyl-2-oxohex-3-yl)-2-(3,4-dimethoxybenzyl)-purin-6one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 9-(6-Phenyl-2-oxohex-3-yl)-2-(3,4-dimethoxybenzyl)-purin-6one
• 英文别名: 2-[(3,4-dimethoxyphenyl)methyl]-9-(2-oxo-6-phenylhexan-3-yl)-1H-purin-6-one
• 化学式: C₂₆H₂₈N₄O₄
• 分子量: 460.5
• InChiKey: GUPZQWXDAQTEDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  94.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：INTRA CELLULAR THERAPIES INC

  公开号：WO2016090382A1

  公开（公告）日：2016-06-09

  The present invention relates to novel PDE2 inhibitory compounds of Formula I as described above, their use as pharmaceuticals and pharmaceutical compositions comprising them.

  本发明涉及如上所述的新型PDE2抑制化合物的化学式I，以及它们作为药物的用途和包含它们的药物组合物。
• Phosphodiesterase inhibitors for the treatment of female sexual dysfunction
  申请人：Pfizer Limited

  公开号：EP1097706A1

  公开（公告）日：2001-05-09

  A method of treating a female suffering from femal sexual dysfunction (FSD), in particular femal sexual arousal dysfunction (FSAD), is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. Said agent is a phosphodiesterase (PDE) inhibitor wherein said PDE is a cAMP hydrolysing PDE (and optionally cGMP hydroysing).

  描述了一种治疗女性性功能障碍（FSD），特别是女性性唤醒功能障碍（FSAD）的方法。该方法包括向女性提供一种能够增强性生殖器内环磷酸腺苷（cAMP）的药物；其中，该药物的量足以引起女性性生殖器内cAMP的增强。该药物可以与药用可接受的载体、稀释剂或赋形剂混合。所述药物是一种磷酸二酯酶（PDE）抑制剂，其中所述PDE是一种cAMP水解PDE（可选地为cGMP水解）。
• [EN] PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS<br/>[FR] PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES EN TANT QU'INHIBITEURS DE LA PDE 2
  申请人：PFIZER PROD INC

  公开号：WO2005061497A1

  公开（公告）日：2005-07-07

  The invention provides compounds of formula (I) prodrugs thereof, and the pharmaceutically acceptable salts of the compounds or prodrugs, wherein n, X, and Y are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof.

  该发明提供了公式（I）的化合物及其前药，以及化合物或前药的药用可接受盐，其中n、X和Y如本文所定义；药物组合物；它们的组合；以及它们的用途。
• [EN] COMPOSITIONS AND METHODS FOR MODULATING LIVER ENDOTHELIAL CELL FENESTRATIONS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR MODULER LES FENESTRATIONS DE CELLULES ENDOTHÉLIALES HÉPATIQUES
  申请人：LECOUTEUR DAVID

  公开号：WO2019109124A1

  公开（公告）日：2019-06-13

  There is provided compositions and methods for modulating the fenestration porosity, fenestration frequency or fenestration diameter of liver endothelial cells. In particular compositions comprising conjugates of quantum dots and a therapeutic are used to modulate the fenestration porosity, frequency or diameter of liver endothelial cells.

  本发明提供了一种调节肝内皮细胞的小孔孔隙度、小孔频率或小孔直径的组合物和方法。具体而言，包含量子点和治疗剂的共轭物被用于调节肝内皮细胞的小孔孔隙度、频率或直径。
• Compounds for the treatment of female sexual dysfunction
  申请人：Pfizer Inc

  公开号：US20040254153A1

  公开（公告）日：2004-12-16

  A method of treating a female suffering from FSD, in particular FSAD, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.

  本发明描述了一种治疗患有女性性功能障碍（FSD），特别是女性性唤起障碍（FSAD）的方法。该方法包括向女性输送一种能够在性生殖器中增强cAMP的药剂；其中该药剂的量足以在女性的性生殖器中引起cAMP的增强。该药剂可以与药学上可接受的载体、稀释剂或赋形剂混合。